Program Guide – ASCO Meeting Program Guide (2024)

Abstracts & Presentations

Patient-reported health-related quality of life (HRQoL) measures collected prior to treatment initiation have been shown to be prognostic of disease outcomes and survival in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), including progression-free survival (PFS) and overall survival (OS), However, these HRQoL measures are usually expressed as numbers from a scale (e.g. from 0 to 100), which limit their ease of clinical utility compared to binary scales (i.e. high vs. low). Using HRQoL measures collected from the phase 3 study GOYA, we aim to convert these measures into binary scales by identifying optimal cutoffs and demonstrate their clinical utility in differentiating patient risks in DLBCL.

Abstract: e23165

Abstracts & Presentations

Intraductal carcinoma of the prostate (IDC-P), considered both a distinct entity (found alone in ~3% of prostate biopsies) and negative prognostic factor of prostatic cancer (identified in ~20% of all patients with prostate cancer). IDC-P represents aggressive disease, and is associated with increased metastasis, recurrence, and prostate cancer-specific death. Given the mortality and rarity of this disease, we analyzed demographic and treatment trends of patients diagnosed with IDC-P in the US.

Abstract: e17011

Abstracts & Presentations

Primary sinonasal mucosal melanoma (SNMM) is a rare and aggressive disease different from cutaneous melanoma. The best treatment modality including the role of immune checkpoint blockade in SNMM has not been defined.

Abstract: e21552

Abstracts & Presentations

Advance penile cancer (APC) is a rare and aggressive malignancy, characterized by the presence of metastases to lymph nodes and/or distant organs. The rarity of patients with APC poses challenges in conducting comprehensive studies, with most existing evidence being small-scale, retrospective analyses from single institutions. Additionally, the absence of large clinical trials limits the evidence to compare the survival rates with different treatment approaches in patients with APC.

Abstract: e17024

Abstracts & Presentations

Approximately 67% of cancer survivors were aged 65 or older in the U.S.; they face a heightened risk of frailty, as both cancer and anti-cancer treatment impose additional stressors on the older adults’ physiological reserves. Inflammatory biomarkers such as serum C-reactive protein (CRP) and Interleukin-6 (IL-6) levels were associated with frailty. However, the role of inflammatory biomarkers on the transitions of frailty states remains unclear. This study aimed to describe transitions between frailty states and death and quantify the predictive effect of inflammatory biomarkers on transitions.

Abstract: e13772

Abstracts & Presentations

Cancer most often affects older adults; 56% of all newly diagnosed cancer patients and 71% of deaths belong to this age group. Frail patients are at increased risk of unfavorable outcomes after Treatment.

Abstract: e13775

Abstracts & Presentations

Advanced lung cancer is diagnosed by imaging through screening, incidental findings, or during the workup of symptoms. Historically, there was no apparent benefit in expediting the times to biopsy, staging, and chemotherapy initiation. However, the widespread first-line use of immune checkpoint inhibitors (ICIs) can introduce delays such as biomarker testing and financial approval. We aimed to test whether the time to ICI treatment initiation was associated with worse clinical outcomes.

Abstract: e21199

Abstracts & Presentations

There is evidence from RCTs demonstrating that our current models of CGA guided care can reduce treatment related toxicity effectively. However, it is unclear if CGA guided care can improve OS and HRQL. We aimed to determine the effect of CGA guided care compared with usual care on OS and HRQL.

Abstract: e24014

Abstracts & Presentations

Portal vein thrombosis (PVT) occurs in 10-40% of patients with hepatocellular carcinoma (HCC). Advanced imaging modalities, such as MRI, can differentiate between bland PVT and tumor thrombus, and help determine the need for anticoagulation (AC). Our study aims to assess the use of AC in patients with HCC and concomitant PVT.

Abstract: e16212

Abstracts & Presentations

Liposarcoma is the most common soft tissue sarcoma and primarily arises in subcutaneous fat of the lower extremities. Previous research has shown socioeconomic factors (eg. Income, insurance status, facility type) to be strongly associated with patterns of care as well as overall survival in bone and soft tissue sarcoma patients. Using the NCDB, this study analyzed the association between income and survival in patients with non-dedifferentiated liposarcoma.

Abstract: e23558

Abstracts & Presentations

To identify preoperative factors associated with survival in pancreatic ductal adenocarcinoma (PDAC) patients who underwent curative-intent surgery after neoadjuvant therapy (NAT) and develop risk stratification criteria.

Abstract: e16312

Abstracts & Presentations

There are no blood-based biomarkers for survival prediction in inoperable stage III NSCLC patients. We propose a method for calculation of novel area under curve (AUC) biomarkers of the dynamic change of multiple leukocyte subpopulations before, during, and after thoracic irradiation (TRT), chemoradiotherapy (CRT), and chemo-radio-immunotherapy (CRT-ICI) in this patient cohort. The extracted biomarkers identify patients with early progression after TRT.

Abstract: e20590

Abstracts & Presentations

RNA methylation is an important epigenetic modification that can act as tumor prognosis biomarkers, and which is regulated by methyltransferase, RNA binding protein, and demethylase. 5-Methylcytosine (m5C) is a well-known post-transcriptional modification that plays an important role in cell differentiation and apoptosis. Although gene mutations in those regulator genes are associated with various cancers, the m5C regulating mechanism and its roles in cancer prognosis largely remains unknown. This study aimed to find new microRNA biomarkers associated with prognosis of clinical outcomes through m5C regulating mechanism in lung squamous cell carcinoma (LUSC).

Abstract: e20568

Abstracts & Presentations

Lung Cancer (LC) is the leading cause of cancer death worldwide and smoking is the leading risk factor. Only 15% of patients with LC are still alive 5 years after diagnosis due to advanced diseases stage at diagnosis. Low-Dose Computed Tomography (LDCT) is the widely accepted standard for screening of individuals at high risk of lung cancer. However, LDCT has several limitations including the high prevalence of non-malignant pulmonary nodules detected leading to overdiagnosis, the potential harms of cumulative radiation dose and poor adherence to recommended follow-up. Therefore, novel blood-based tests could offer a simple follow confirmation approach and this test is designed to find those patients who DO NOT have cancer.

Abstract: e20533

Abstracts & Presentations

Platinum-based chemotherapy plus irinotecan or etoposide is the standard of care for first line (1L) treatment of small cell lung cancer (SCLC). Sensitivity to platinum-based chemotherapy has implications for regimen choice in subsequent lines of treatment. The goal of this study was to examine differences in patient characteristics, treatment patterns, and survival associated with the management of SCLC in a Medicare population by platinum sensitivity status, i.e., platinum sensitive (PS) or platinum refractory (PR).

Abstract: e20617

Abstracts & Presentations

Thymoma is an uncommon malignancy often associated with paraneoplastic syndromes including pure red cell aplasia (PRCA), occurring in up to 5% of patients with thymoma. Considering the rarity of thymoma-associated PRCA, optimal treatment regimens and impact on thymoma disease course have yet to be established.

Abstract: e20625

Abstracts & Presentations

Programmed death-ligand 1 (PD-L1) is a crucial biomarker predicting efficacious treatment of immune checkpoint inhibitors (ICIs). Previous studies identified distinct staining utility among multiple PD-L1 antibodies, however, whether the genomic correlate of stained PD-L1 is also impacted by different testing assays is largely unknown.

Abstract: e20526

Abstracts & Presentations

Over 50% early stage NSCLC patients would suffer from recurrence and distant metastasis. Neoadjuvant TKI therapy had been explored aiming to reduce recurrence and metastasis. Erlotinib neoadjuvant therapy (NAT) significantly improved ORR, PFS and major pathologic response (MPR) rate in trial EMERGING/CTONG1103. In our hospital, some patients received extended neoadjuvant treatment because of continued lesion remission. These patients eventually received surgery when the lesions stopped remission and achieved remarkable pathologically complete remission (pCR) rate. Herein we analyzed the efficacy of extended NAT.

Abstract: e20500

Abstracts & Presentations

Metastasis tumor is the leading cause of lung cancer-related deaths, including local metastasis and distant metastasis. Despite its crucial clinical significance, local metastasis of lung cancer is still largely uncharacterized in terms of underlying molecular mechanisms. Here, we performed TSO500 (Illumina, San Diego, CA, USA) sequencing with 19 matched lung cancer primary and local metastatic samples to comprehensively profiling of lung cancer molecular characteristics.

Abstract: e20517

Abstracts & Presentations

Epidermal growth factor receptor (EGFR) mutation have been demonstrated to be both predictive and prognostic for patients with metastatic lung cancer. The administration of EGFR tyrosine kinase inhibitors (TKIs) has improved survival in this group of patients. Several generations of EGFR TKIs are currently available. The EGFR mutations have been divided into common and rare. The common mutations include Exon 19 deletion and Exon 21 L858R mutations and rest are grouped as rare. The presence of visceral metastasis in the brain and liver are usually portends a poor prognosis.

Abstract: e20518